Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Kilvaer, Thomas K ^a   Valkov, Andrej ^a,b   Sorbye, Sveinung W ^a,b   Smeland, Eivind ^b   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a,b   Donnem, Tom ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PLATELET DERIVED GROWTH FACTOR B; VASCULOTROPIN RECEPTOR 3;

ADOLESCENT; ADULT; AGED; ANGIOSARCOMA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; HUMAN; HUMAN TISSUE; INFANT; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; NERVE SHEATH TUMOR; NEUROFIBROSARCOMA; PLEOMORPHIC SARCOMA; PRESCHOOL CHILD; PROGNOSIS; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SCHOOL CHILD; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TUMOR VASCULARIZATION; CELL MOTION; DISEASE FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMOR; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); OBSERVER VARIATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SARCOMA; TISSUE MICROARRAY; VASCULARIZATION;

ADULT; CELL MOVEMENT; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; OBSERVER VARIATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SARCOMA; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; YOUNG ADULT;

EID: 79959892653     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-104     Document Type: Article

References (30)

1. Fletcher CDM, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone. 2002, Lyon: IARC Press.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
3. Dickinson IC, Whitwell DJ, Battistuta D, Thompson B, Strobel N, Duggal A, Steadman P. Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J Surg 2006, 76(3):104-109. 10.1111/j.1445-2197.2006.03615.x, 16626341.
4. Mendenhall WM, Indelicato DJ, Scarborough MT, Zlotecki RA, Gibbs CP, Mendenhall NP, Mendenhall CM, Enneking WF. The management of adult soft tissue sarcomas. Am J Clin Oncol 2009, 32(4):436-442. 10.1097/COC.0b013e318173a54f, 19657238.
5. Kaushal A, Citrin D. The role of radiation therapy in the management of sarcomas. Surg Clin North Am 2008, 88(3):629-646. 10.1016/j.suc.2008.03.005, 2517216, 18514703.
6. Thornton K. Chemotherapeutic management of soft tissue sarcoma. Surg Clin North Am 2008, 88(3):647-660. 10.1016/j.suc.2008.03.004, 18514704.
7. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009, 8(3):235-253. 10.1038/nrd2792, 19247306.
8. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16(2):159-178. 10.1016/j.cytogfr.2005.01.004, 15863032.
9. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol 2001, 12(10):1423-1432. 10.1023/A:1012527006566, 11762815.
10. Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol 2004, 15(8):1261-1266. 10.1093/annonc/mdh309, 15277268.
11. Yoon SS, Segal NH, Park PJ, Detwiller KY, Fernando NT, Ryeom SW, Brennan MF, Singer S. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res 2006, 135(2):282-290. 10.1016/j.jss.2006.01.023, 16603191.
12. Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol 1999, 125(10):577-581. 10.1007/s004320050319, 10473871.
13. Hu M, Nicolson GL, Trent JC, Yu D, Zhang L, Lang A, Killary A, Ellis LM, Bucana CD, Pollock RE. Characterization of 11 human sarcoma cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors. Cancer 2002, 95(7):1569-1576. 10.1002/cncr.10879, 12237927.
14. Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Brakenhielm E, Cao Y. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007, 117(10):2766-2777. 10.1172/JCI32479, 1994630, 17909625.
15. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA 2002, 99(13):8868-8873. 10.1073/pnas.062040199, 124390, 12070340.
16. Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, Reynolds AR. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2010,
17. Kilvaer TK, Valkov A, Sorbye S, Smeland E, Bremnes RM, Busund LT, Donnem T. Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis. PLoS One 2010, 5(12):e15368. 10.1371/journal.pone.0015368, 3001883, 21179485.
18. Kilvaer TK, Valkov A, Sorbye SW, Donnem T, Smeland E, Bremnes RM, Busund LT. Platelet-Derived Growth Factors in Non-GIST Soft-Tissue Sarcomas Identify a Subgroup of Patients with Wide Resection Margins and Poor Disease-Specific Survival. Sarcoma 2010, 2010(2010):10..
19. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997, 15(1):350-362.
20. Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT, Bremnes RM. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007, 13(22 Pt 1):6649-6657.
21. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA, Franklin WA. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002, 20(10):2417-2428. 10.1200/JCO.2002.08.159, 12011119.
22. Ohshima M, Yamaguchi Y, Kappert K, Micke P, Otsuka K. bFGF rescues imatinib/STI571-induced apoptosis of sis-NIH3T3 fibroblasts. Biochem Biophys Res Commun 2009, 381(2):165-170. 10.1016/j.bbrc.2009.02.012, 19338769.
23. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
24. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005, 16(2):233-247. 10.1016/j.cytogfr.2005.01.007, 15863038.
25. Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellstrom M, Backstrom G, Fredriksson S, Landegren U, Nystrom HC, Bergstrom G, Dejana E, Ostman A, Lindahl P, Betsholtz C. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003, 17(15):1835-1840. 10.1101/gad.266803, 196228, 12897053.
26. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003, 112(8):1142-1151. 213487, 14561699.
27. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 2004, 15(4):215-228. 10.1016/j.cytogfr.2004.03.005, 15207813.
28. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454(7204):656-660. 10.1038/nature07083, 18594512.
29. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005, 65(3):550-563. 10.1016/j.cardiores.2004.12.002, 15664381.
30. Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009, 4(5):578-585. 10.1097/JTO.0b013e31819f2e38, 19318994.